A Randomized Phase III Trial Comparing Trabectedin (Yondelis) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma

Trial Profile

A Randomized Phase III Trial Comparing Trabectedin (Yondelis) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2018

At a glance

  • Drugs Trabectedin (Primary) ; Dexamethasone
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms TSAR
  • Sponsors Gustave Roussy cancer campus
  • Most Recent Events

    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 17 May 2018 According to a PharmaMar media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO).
    • 11 Oct 2016 Primary endpoint (Progression Free Survival) has been met,according to the results published at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top